Chronic liver disease in the extremely elderly of 80 years or more: clinical characteristics, prognosis and patient survival analysis

被引:33
作者
Hoshida, Y [1 ]
Ikeda, K [1 ]
Kobayashi, M [1 ]
Suzuki, Y [1 ]
Tsubota, A [1 ]
Saitoh, S [1 ]
Arase, Y [1 ]
Kobayashi, M [1 ]
Murashima, N [1 ]
Chayama, K [1 ]
Kumada, H [1 ]
机构
[1] Toranomon Gen Hosp, Div Gastroenterol, Minato Ku, Tokyo 1058470, Japan
关键词
chronic liver disease; extremely elderly patients; liver cancer appearance rate; survival analysis;
D O I
10.1016/S0168-8278(99)80287-6
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: This study aimed to elucidate the clinical characteristics of patients with chronic liver disease aged 80 years or more, especially the factors affecting prognosis and carcinogenesis. Methods: A total of 135 patients aged 80 years or above were divided into chronic liver disease without cirrhosis (non-LC) and cirrhosis (LC) groups according to the severity of fibrosis, and the clinical characteristics and prognoses were evaluated. Results: Seventy-three (54.1%) of 135 patients were in the LC group and 79 patients (58.5%) had hepatitis C virus. Various concomitant diseases were seen in 122 patients (90.4%), Liver-related deaths occurred in only 19 (36.5%) of 52 patients who died during observation, although 28 patients (53.8%) had liver cancer at the time of death, Cumulative survival rates in the non-LC and the LC groups were 85.7% and 58.8% at the 5th year, and 69.4% and 19.4% at the 9th year, respectively, Cumulative liver cancer appearance rates in the non-LC and the LC groups were 1.6% and 6.1% at the Ist year, 12.4% and 19.9% at the 5th year, and 12.4% and 32.0% at the 7th year, respectively. A multivariate Cox regression analysis revealed that the presence of liver cancer (p=0.0001), platelet count (p=0.0242), and fibrotic stage (p=0.0118) were independently associated with survival period, and alfa-fetoprotein (p=0.0194) and bilirubin (p=0.0282) were independently associated with carcinogenesis. Conclusions: Cirrhosis is the major risk factor affecting the prognosis. On the other hand, we must pay more attention to concomitant diseases specific to advanced age.
引用
收藏
页码:860 / 866
页数:7
相关论文
共 57 条
[1]  
ALVAN RF, 1985, NEW ENGL J MED, V312, P1604
[2]  
[Anonymous], 1990, ANN SURG, V211, P277
[3]   THE USE OF RECOMBINANT INTERFERON ALFA-2B IN ELDERLY PATIENTS WITH ANTI-HCV-POSITIVE CHRONIC ACTIVE HEPATITIS [J].
BRESCI, G ;
DELCORSO, L ;
ROMANELLI, AM ;
GIULIANO, G ;
PENTIMONE, F .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1993, 41 (08) :857-862
[4]  
Brind AM, 1996, QJM-INT J MED, V89, P291
[5]   Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma:: Results of a randomized, controlled trial in a single institution [J].
Bruix, J ;
Llovet, JM ;
Castells, A ;
Montañá, X ;
Brú, C ;
Ayuso, MD ;
Vilana, R ;
Rodés, J .
HEPATOLOGY, 1998, 27 (06) :1578-1583
[6]  
CHIARAMONTE M, 1987, BIOMED PHARMACOTHER, V41, P121
[7]   CLINICAL-FEATURES AND PROGNOSIS OF HEPATOCELLULAR-CARCINOMA IN BRITAIN IN RELATION TO AGE [J].
COLLIER, JD ;
CURLESS, R ;
BASSENDINE, MF ;
JAMES, OFW .
AGE AND AGEING, 1994, 23 (01) :22-27
[8]   ALTERATIONS IN THE HUMAN IMMUNE-RESPONSE TO THE HEPATITIS-B VACCINE AMONG THE ELDERLY [J].
COOK, JM ;
GUALDE, N ;
HESSEL, L ;
MOUNIER, M ;
MICHEL, JP ;
DENIS, F ;
RATINAUD, MH .
CELLULAR IMMUNOLOGY, 1987, 109 (01) :89-96
[9]  
COX DR, 1972, J R STAT SOC, V34, P248
[10]   IMMUNOGENICITY OF STANDARD AND LOW-DOSE VACCINATION USING YEAST-DERIVED RECOMBINANT HEPATITIS-B SURFACE-ANTIGEN IN ELDERLY VOLUNTEERS [J].
DERAVE, S ;
HEIJTINK, RA ;
BAKKERBENDIK, M ;
BOOT, J ;
SCHALM, SW .
VACCINE, 1994, 12 (06) :532-534